Benztropine-analog DAT Inhibitors
Attention Deficit/Hyperactivity Disorder (ADHD)
PreclinicalActive
Key Facts
Indication
Attention Deficit/Hyperactivity Disorder (ADHD)
Phase
Preclinical
Status
Active
Company
About P2D Bioscience
Founded in 2016, P2D Bioscience is a private, preclinical-stage biotech developing novel therapeutics for CNS inflammatory disorders. Its pipeline features two distinct drug candidate classes: orally active isoindoline TNFα inhibitors for FTD and AD, and benztropine-analog dopamine transporter (DAT) inhibitors for ADHD. The company's strategy is to advance candidates through early clinical proof-of-concept before seeking partnerships for later-stage development and commercialization. P2D operates as a virtual or asset-centric company, leveraging experienced management and a focused platform to de-risk programs for potential partners.
View full company profileOther Attention Deficit/Hyperactivity Disorder (ADHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT120 | Definium Therapeutics | Proof-of-Concept |